position which profits with stock below $21.35 at expiration. Secondaries (announced/priced): N/A IPO's: Cancer Genetics (CGIX) files $50M through MBlair & Baird Key Research: Barcap upgrades RPXC/CYMI/LSI/MU & downgrades AMAT/CODE/FSL/INTC/MCHP & initiates CXS (ew) and WPX (ow) Key Research: Citi upgrades